Q-omics provides the consensus-scored TBX10 profile across patient tissues and cancer cell-line models. TBX10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TBX10 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, TBX10 RNA expression shows 13,874 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where TBX10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX10 survival associations across molecular data types. TBX10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX10 RNA expression–survival associations across cancer types. High TBX10 expression shows unfavorable associations in KIRC, BRCA and UVM, but favorable associations in HNSC, SCLC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for TBX10 RNA expression.
This table summarizes TBX10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TBX10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX10 shows lower tumor expression in COAD and READ and higher tumor expression in LIHC, UCEC, LUAD and LUSC. The LIHC box plot shows higher TBX10 RNA expression in tumor versus normal tissue (log2 FC = +0.969, t-test p < 0.001).
This table shows molecular features associated with TBX10 in patient tissues and cancer cell lines. In patient samples, TBX10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
